Sumitomo Pharma Third Quarter 2025 Earnings: Beats Expectations

Sumitomo Pharma (TSE:4506) Third Quarter 2025 Results

Key Financial Results

• Revenue: JP¥112.4b (up 37% from 3Q 2024).
• Net income: JP¥53.4b (up from JP¥50.0b loss in 3Q 2024).
• Profit margin: 48% (up from net loss in 3Q 2024). The move to profitability was primarily driven by lower expenses.
• EPS: JP¥135 (up from JP¥126 loss in 3Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sumitomo Pharma Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 24%. Earnings per share (EPS) also surpassed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are up 2.7% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Sumitomo Pharma you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.